These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Psychotropic medication use in children and adolescents in an inpatient setting. Pejovic-Milovancevic M; Miletic V; Popovic-Deusic S; Draganic-Gajic S; Lecic-Tosevski D; Marotic V Psychiatriki; 2011; 22(4):314-9. PubMed ID: 22271844 [TBL] [Abstract][Full Text] [Related]
23. Therapeutic drug monitoring for the treatment of psychiatric disorders. Clinical use and cost effectiveness. Eilers R Clin Pharmacokinet; 1995 Dec; 29(6):442-50. PubMed ID: 8787949 [TBL] [Abstract][Full Text] [Related]
24. Drug interactions in psychopharmacology. Callahan AM; Fava M; Rosenbaum JF Psychiatr Clin North Am; 1993 Sep; 16(3):647-71. PubMed ID: 8415238 [TBL] [Abstract][Full Text] [Related]
25. [Polypharmacy of psychotropic drugs in child and adolescent psychiatry in Germany - rather the rule than the exception]. Vloet TD; Egberts K; Taurines R; Wewetzer C; Mehler-Wex C; Plener PL; Romanos M; Gerlach M Z Kinder Jugendpsychiatr Psychother; 2019 May; 47(3):193-202. PubMed ID: 30422047 [TBL] [Abstract][Full Text] [Related]
26. Ethical and pragmatic issues in the use of psychotropic agents in young children. Jensen PS Can J Psychiatry; 1998 Aug; 43(6):585-8. PubMed ID: 9729685 [TBL] [Abstract][Full Text] [Related]
27. Psychotropic drug concentrations and clinical outcomes in children and adolescents: a systematic review. Kloosterboer SM; Vierhout D; Stojanova J; Egberts KM; Gerlach M; Dieleman GC; Hillegers MHJ; Passe KM; Gelder TV; Dierckx B; Koch BCP Expert Opin Drug Saf; 2020 Jul; 19(7):873-890. PubMed ID: 32421365 [TBL] [Abstract][Full Text] [Related]
28. French summaries of product characteristics: content in relation to therapeutic monitoring of psychotropic drugs. Rougemont M; Ulrich S; Hiemke C; Corruble E; Baumann P Fundam Clin Pharmacol; 2010 Jun; 24(3):377-84. PubMed ID: 20199581 [TBL] [Abstract][Full Text] [Related]
29. [Clinical significance of pharmacogenetics in psychiatry]. Skrętkowicz J; Barańska M; Rychlik-Sych M Wiad Lek; 2013; 66(2 Pt 2):185-91. PubMed ID: 25775815 [TBL] [Abstract][Full Text] [Related]
31. Building a treatment safety net for children in child welfare programs. Bellonci C; Gleason MM J Am Acad Child Adolesc Psychiatry; 2012 Sep; 51(9):855-7. PubMed ID: 22917196 [No Abstract] [Full Text] [Related]
32. [Safety and tolerability of psychotropic medications in childhood: preliminary data of a pharmacovigilance study]. Magazù A; Masi G; Germanò E; Gagliostro MS; Siracusano R; Arcoraci V; Spina E; Gagliano A Minerva Pediatr; 2014 Jun; 66(3):187-99. PubMed ID: 24826975 [TBL] [Abstract][Full Text] [Related]
34. [Particularities and problems of psychopharmacology in childhood and adolescence]. Gerlach M; Renner T; Romanos M Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2023 Jul; 66(7):761-766. PubMed ID: 37277511 [TBL] [Abstract][Full Text] [Related]
35. Use of drugs in child and adolescent psychiatry. Kaplan CA; Hussain S Br J Psychiatry; 1995 Mar; 166(3):291-8. PubMed ID: 7788118 [TBL] [Abstract][Full Text] [Related]
36. [Children and adolescents with mental disorders as orphans of managed care?]. Fegert JM; Rothärmel S Prax Kinderpsychol Kinderpsychiatr; 2000 Feb; 49(2):127-32. PubMed ID: 10721275 [TBL] [Abstract][Full Text] [Related]
37. Are non-serious adverse reactions to psychiatric drugs really non-serious? Pozzi M; Bertella S; Cattaneo D; Molteni M; Perrone V; Carnovale C; Antoniazzi S; Clementi E; Radice S J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):394-400. PubMed ID: 23952186 [TBL] [Abstract][Full Text] [Related]
38. Commentary: confessions of a prescription writer. Combrinck-Graham L J Marital Fam Ther; 2002 Jan; 28(1):47-50. PubMed ID: 11813365 [No Abstract] [Full Text] [Related]